论文部分内容阅读
血栓素A_2(thromboxane A_2,TxA_2)于1975年发现,并证明是一种使血小板聚集和血管平滑肌收缩的物质,其t_(1/2)为30秒。由于当时对其化学性质不明,它在病程中的重要中介作用未被识破。后来明确了它的化学结构,以及它被聚集的血小板释放后、又反馈作用于其它血小板,始重视了它在心血管病中的重要中介作用。最近证实,血小板及血管平滑肌有特异性血栓素受体(TxR),为研究TxA_2的作用增加了重要工具。目前已将TxA_2看成是急性生命紧迫性病症(如缺血及休克)的强而重要的中介物质。已经证明TxA_2在心肺性疾病中有四个
Thromboxane A 2 (TxA 2) was discovered in 1975 and has been shown to be a substance that causes platelet aggregation and vascular smooth muscle contraction with a t½ (1/2) of 30 seconds. Due to its unknown chemical properties at the time, its important intermediary role in the course of disease has not been identified. Later, it was clarified its chemical structure, and its release of aggregated platelets, and feedback on the role of other platelets, initially attached importance to its cardiovascular disease in the important intermediary role. Recently, it has been confirmed that there is a specific thromboxane receptor (TxR) in platelets and vascular smooth muscle, which adds an important tool for the study of the effect of TxA_2. TxA 2 has now been considered as a strong and important mediator of acute life-threatening conditions such as ischemia and shock. It has been shown that TxA 2 has four of cardio-pulmonary diseases